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Abstract Joint modeling of longitudinal and survival data can provide more efﬁcient and
less biased estimates of treatment effects through accounting for the associations between
these two data types. Sponsors of oncology clinical trials routinely and increasingly include
patient-reported outcome (PRO) instruments to evaluate the effect of treatment on
symptoms, functioning, and quality of life. Known publications of these trials typically do
not include jointly modeled analyses and results. We formulated several joint models based
on a latent growth model for longitudinal PRO data and a Cox proportional hazards model
for survival data. The longitudinal and survival components were linked through either a
latent growth trajectory or shared random effects. We applied these models to data from a
randomized phase III oncology clinical trial in mesothelioma. We compared the results
derived under different model speciﬁcations and showed that the use of joint modeling may
result in improved estimates of the overall treatment effect.
Keywords Joint modeling   Cox proportional hazards model   Latent trajectory  
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1 Introduction
Clinical research often generates both longitudinal and survival (time-to-event) data. Well-
established methods exist for separately analyzing each type of data. For longitudinal data,
mixed-effects models for repeated measures (MMRM) are often used, which can handle
data that is missing at random. For survival data, semiparametric methods such as Cox
proportional hazards models and parametric methods such as Weibull models are com-
monly used. Although useful, separate analyses of each type of outcome may not be able to
provide adequate answers to some important research questions. One such example is
whether CD4 lymphocyte count could serve as a good surrogate marker for clinical pro-
gression in AIDS clinical trials (Tsiatis et al. 1995). Another example is whether changes
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disease status in patients with schizophrenia, are associated with the time to discontinu-
ation of therapy (Henderson et al. 2000).
To answer these questions, methods for the combined analysis of the two types of data
have been developed recently. A naive method is to incorporate the longitudinal measures
directly into the Cox model as time-varying covariates. As noted by researchers (e.g.,
Tsiatis et al. 1995; Yu et al. 2004), this method does not account for measurement errors in
the time-varying covariates and therefore can cause the estimated relative risk parameter in
the time-dependent Cox model to be biased toward the null (Prentice 1982).
Tsiatis et al. (1995) proposed a two-stage approach to improve the naive method. In this
approach, a linear mixed-effects model is ﬁt to the longitudinal data, and then the ﬁtted
trajectory is incorporated into the Cox model as time-varying covariates. However, this
approach has the potential for biased estimates when the longitudinal process is infor-
matively censored at the event time (Hanson et al. 2011).
Disadvantages of the naive method and two-stage approach motivated the recent
development of joint models for longitudinal and survival data (see Tsiatis and Davidian
2004 for a review). In joint models, there are two components: a longitudinal process and a
survival process. For individual i, the longitudinal process, Yi(t), is modeled with an
underlying latent process gi(t) and the deviations ei(t) due to the measurement error and
biological variation, i.e., Yi(t) = gi(t) ? ei(t). In this paper, we use latent growth models
for longitudinal data given their strengths such as (1) occasions of measurement need not
be equally spaced, (2) the models can account for both measured and unmeasured
covariates, (3) the models can account for measurement errors, and (4) as in general
structural equation models, statistical models are ﬂexible. In the survival process, event
time Ti depends on gi(t) or random effects included in gi(t) or both. Joint likelihoods are
speciﬁed based on these two components, then estimation and inferences are made using
frequentist (Wulfsohn and Tsiatis 1997; Henderson et al. 2000; Song et al. 2002)o r
Bayesian (Faucett and Thomas 1996; Xu and Zeger 2001; Wang and Taylor 2001; Brown
and Ibrahim 2003; Guo and Carlin 2004; Hatﬁeld et al. 2011) approaches.
Several advantages have been noted with joint modeling (Ibrahim et al. 2010): (1) It
addresses the informative censoring induced from the absence of longitudinal observations
beyond the event time (Muthe ´n et al. 2009); (2) It reduces estimation biases by accounting
for measurement error and informative censoring; (3) It may increase statistical efﬁciency
by using all of the data simultaneously in a single model; (4) It allows inferences for all
three aspects: the treatment effect on longitudinal process; the association between the
longitudinal process and survival; and the treatment effect on survival including the direct
treatment effect on survival, the indirect treatment effect on survival through the latent
longitudinal process, and therefore the overall treatment effect on survival, which is the
sum of the direct and indirect effect.
Sponsors of oncology clinical trials routinely and increasingly include patient-reported
outcome (PRO) measures over time to evaluate the effect of treatment on symptoms,
functioning, and quality of life (QoL). PRO data, along with tumor progression and overall
survival rate, provide a comprehensive assessment of beneﬁt and risk for treatment in late-
stage cancer. Treatment that delays tumor progression is often associated with better
symptoms and QoL progress. On the other hand, improvement in symptoms and QoL may
serve as an indicator of a positive tumor response or lack of tumor progression. As an
effective treatment often impacts both tumor progression/survival and symptoms simul-
taneously, it is important to understand the impact of a treatment on both outcomes and the
association between two types of outcomes through joint modeling.
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clinical trial in patients with malignant pleural mesothelioma (MPM) (Vogelzang et al.
2003). Researchers in this Vogelzang et al. (2003) study (also known as EMPHACIS)
collected PRO measures throughout the course of treatment, using the patient-reported
Lung Cancer Symptom Scale (LCSS) (Hollen et al. 1995). Previously, researchers have
investigated the prognostic effect of baseline PRO measures on overall survival in patients
with MPM (Bottomley et al. 2007). We however were interested in the association
between post-baseline PRO scores and time to progressive disease (TTPD). The main goal
of applying joint models in this study was to assess the treatment effect on LCSS symp-
toms and global measures of functioning and QoL, the association between the longitudinal
LCSS items and TTPD, and the overall treatment effect on TTPD.
The remainder of this paper is organized as follows. In Sect. 2, we describe the
EMPHACIS dataset. In Sect. 3, we formulated several joint models based on a latent
growth model for longitudinal PRO data and a Cox proportional hazard model for survival
data. The longitudinal and survival components were linked through either a latent growth
trajectory or shared random effects. We adopted the path diagrams to visually represent the
joint models; these diagrams help to illustrate the indirect and direct relationships among
observed and latent variables. Section 4 presents results from our joint models applied to
the EMPHACIS datasets with detailed interpretation. In addition, results from the joint
modeling approach were compared with the results from separate modeling approaches.
We conclude in Sect. 5 with a discussion of results and limitations of the joint modeling
approach, and offer suggestions concerning model extensions.
2 Motivating example, the MPM clinical trial
2.1 Patients
EMPHACIS was a global phase III clinical trial conducted to evaluate the efﬁcacy of
pemetrexed/cisplatin, compared with cisplatin alone, as ﬁrst-line treatment for patients
with MPM (Vogelzang et al. 2003).
A total of 448 eligible patients were randomly assigned and received therapy
(pemetrexed/cisplatin, n = 226; cisplatin alone, n = 222), and they were considered as the
intent-to-treat (ITT) population. Pemetrexed/cisplatin or cisplatin was administered on day
1 of a 21-day cycle. A regimen of pemetrexed/cisplatin or cisplatin was deﬁned as six
cycles of therapy. A patient who was receiving beneﬁt from treatment could receive
additional cycles based on the discretion of the investigator. Treatment was discontinued
for disease progression or intolerable toxicity, or on patient or investigator request.
Pemetrexed/cisplatin patients received more treatment cycles (median, 6 cycles; range,
1–12 cycles) than those receiving cisplatin alone (median, 4 cycles; range, 1–9 cycles).
The TTPD was the time from randomization until a documented progression or death from
any cause. For patients without progressive disease at the time of analysis, the date of the last
follow-upwasconsideredright-censored.Vogelzanget al.(2003)showedanincreasedTTPDof
1.8 months (median 5.7 months in pemetrexed/cisplatin versus 3.9 months in cisplatin alone).
2.2 Patient-reported outcome measures
The PROs were measured with the well-established and validated LCSS, a nine-item
instrument scored through responses that patients recorded on 100-mm visual analog scales,
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123with zero representing absence of the symptoms or impairment, or high QoL, and 100
representingasmuchsymptomsorimpairmentastherecouldbeorlowQoL.Theninescales
representsixlung-cancer-relatedsymptoms(anorexia,cough,dyspnea—shortnessofbreath,
fatigue, hemoptysis, and pain) and three global measures (symptom distress, interference
with carrying out normal activities, and global QoL). To be consistent with the LCSS
validationstudiesinmesothelioma(Hollenet al.2006),whichindicatedthathemoptysiswas
not a relevant symptom in patients with MPM, we excluded hemoptysis from our analyses.
Accordingly,we includedtwoaverage symptomburdenindices(ASBIs)in ouranalyses:the
ASBI5 (the mean of the ﬁve remaining symptom items: anorexia, cough, dyspnea, fatigue,
and pain) and the ASBI8 (the mean of the ﬁve symptom items and the three global items).
The LCSS assessments were scheduled at two baseline visits (4–6 days and 1–2 days
before the start of study drug therapy), weekly during the study (at days 8 ± 1, 15 ± 1, and
19ofeach cycle), andapproximatelyevery3 monthsafterthepatient hadreceived hisorher
last dose of treatment if the patient had not initiated subsequent therapy. To eliminate intra-
cycle variability in the LCSS scores and reduce computational burden, we calculated the
mean of each patient’s scores for each LCSS item within each cycle. Accordingly, for each
cycle the LCSS were assessed, we included the corresponding measurement time into the
models as the mean number of days from randomization to LCSS assessments within the
cycle.
Before disease progression or death, over 90 % of the patients completed LCSS
assessments at each cycle per study protocol. Beyond disease progression, very few LCSS
assessments were available. Given one of our primary interests was to assess the associ-
ation between the TTPD and LCSS scores obtained prior to TTPD, we excluded the LCSS
measurements obtained after tumor progression. In addition, considering that the protocol
deﬁned regimen was 6 cycles, we excluded the LCSS measurements obtained after cycle 6,
which allowed us to focus on the treatment effect on the LCSS scores within the ﬁrst 6
cycles. Only 20 (4.5 %) patients received more than 6 cycles of treatment; the exclusion of
these data should have little impact on our results. Termination of LCSS measurements
was closely related to TTPD, which introduced the problem of informative censoring.
3 Methods
For individual i, let Yij be the observed longitudinal data at times tij;j ¼ 0;...;Ji, and let
gi(t) be the latent trajectory function underlying Yij. Let Ti be the observed event time,
which is the minimum of the event time Ti
0 and the censoring time Ci. Let di be the
censoring indicator,
di ¼ 1; if T0
i [Ci;censored
0; if T0
i  Ci;event:
 
Let Zi be the treatment indicator, Zi = 1 if individual i received pemetrexed/cisplatin and
Zi = 0 if cisplatin was received, so that treatment effect refers to pemetrexed/cisplatin
versus cisplatin.
3.1 Separate analyses
Before looking into the joint models, we performed separate analyses for longitudinal data
and survival data. When longitudinal data are incomplete, the MMRM is a commonly used
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123method (Siddiqui et al. 2009). We included treatment, cycle, and treatment-by-cycle
interaction as ﬁxed effects and BIC was used to choose between compound symmetry and
AR(1) covariance matrices in the MMRM analysis.
For the survival data, we ﬁt the Cox proportional hazards model with treatment as the
only covariate (Cox 1975), i.e.,
loghiðtÞ¼logh0ðtÞþaZi;
where hi(t) and h0(t) are the hazard function for individual i and the baseline hazard
function.
3.2 Cox model with time-varying covariates
We also performed the combined analysis that incorporated the longitudinal measures
directly into the Cox model as time-varying covariates. This method can be described as
loghiðtÞ¼logh0ðtÞþX0
sia þ cYiðtÞ;
where X0
si is the covariate vector affecting survival that may include treatment (Zi) and
other covariates, a is the corresponding coefﬁcient vector, and c measures the association
between longitudinal measures and survival. This naive method does not account for
measurement errors of longitudinal outcome.
3.3 Joint models for longitudinal data and survival data
Joint models have two linked components: the longitudinal component and the survival
component. The longitudinal component consists of a model for longitudinal outcome, in
which a trajectory function is often speciﬁed. The survival component consists of a model
for survival data. We describe two types of joint models in which the longitudinal and
survival components are linked differently. Both types of models use the following latent
growth model to describe the longitudinal data,
Yij ¼ giðtijÞþeij ð1Þ
giðtÞ¼fðtÞ
Tbi ð2Þ
bi ¼ bXi þ fi ð3Þ
where eij  Nð0;r2Þ are mutually independent measurement errors, fðtÞ is a vector of
functions of t;bi is an individual speciﬁc parameter vector (random effects), b is a
regression parameter matrix, and fi are residuals following a multivariate normal distri-
bution with mean zero and variance covariance matrix Rr r.
The formulation of the longitudinal model above offers great ﬂexibility and links
well to the commonly used mixed-effects models. For example, consider a mixed-effects
model, Yij ¼ b00 þ b10tij þ b11Zitij þ f0i þ f1itij þ eij; where the ﬁxed-effects part is b00 ?
b10tij ? b11Zi tij, assuming a treatment-by-time interaction, and the random-effects part is
f0i þ f1itij. This model can be easily written in the latent growth model format with the
following speciﬁcation:
fðtÞ¼ð 1;tÞ
0; bi ¼ð b0i;b1iÞ
0; b ¼ b00 0
b10 b11
  
; Xi ¼ð 1;ZiÞ
0; fi ¼ð f0i;f1iÞ:0
This model is introduced as l_s below.
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123In our analysis, we considered ﬁve choices of gi(t) depending on the shape of the
trajectory function and the treatment effect associated with the trajectory function. The ﬁrst
three choices, named l_s, l_i, and l_is assume a linear growth for each LCSS item, i.e.,
gi(t) = b0i ? b1it. In addition, model l_s assumes treatment effect on slope only
(b0i ¼ b00 þ f0i;b1i ¼ b10 þ b11Zi þ f1i); model l_i assumes treatment effect on intercept
only; and model l_is assumes treatment effect on both intercept and slope. The other
two choices, named q_s and q_sq, assume a quadratic growth for each LCSS item,
i.e., gi(t) = b0i ? b1it ? b2it
2. Model q_s assumes treatment effect on slope only (b0i ¼
b00 þ f0i;b1i ¼ b10 þ b11Zi þ f1i; b2i ¼ b20 þ f2i) and model q_sq assumes treatment
effect on both slope and quadratic coefﬁcient. In models l_s, l_is, q_s, and q_sq, where a
treatment effect on slope is assumed, a treatment-by-time interaction is explicitly assumed.
We checked the treatment effect on the intercept in the two linear growth models although
we expect that there is no difference at baseline across treatment groups for this ran-
domized trial.
3.3.1 Trajectory model
In the trajectory model, the longitudinal and survival components are linked through the
latent trajectory. For example, Xu and Zeger (2001) proposed to use a Markov Chain
Monte Carlo algorithm to estimate the posterior distribution for parameters in the joint
model in which the survival component consists of
loghiðtÞ¼logh0ðtÞþX0
sia þ cgiðtÞ; ð4Þ
where c measures the association between survival and the trajectory gi(t) that varies
continuously over time.
An alternative way to describe the survival component was proposed by Asparouhov
et al. (2006) and is detailed here. First, the time interval is split into subintervals
[tk-1, tk), k = 1, 2,…,K, t0 = 0, tK ¼1 ; and a separate survival variable Tik and cen-
soring indicator dik are created for each subinterval [tk-1, tk) from the original survival
variable Ti and censoring indicator di as follows:
Tik ¼
tk   tk 1; if tk\Ti;
missing; if Ti\tk 1;
Ti   tk 1; otherwise;
8
<
:
dik ¼
1; if tk\Ti;
missing; if Ti\tk 1;
di; otherwise:
8
<
:
ð5Þ
Then, for t in the time interval [tk-1, tk),
loghikðtÞ¼logh0ðtÞþX0
sia þ cgiðtk 1Þ; ð6Þ
h0(t) is a non-parametric baseline hazard function, and the likelihood for the survival
variable tKi-1 B Ti\tKi is
pðTi;dijbi;a;cÞ¼
Y Ki
k¼1
hikðTikÞ
ð1 dikÞexp  
X Ki
k¼1
Z tk 1þTik
tk 1
hikðsÞds
()
: ð7Þ
This model uses the stepwise predictor gi(tk-1) and is estimated by the maximum likeli-
hood algorithm. If the step size is chosen to be sufﬁciently small, the difference between
this model and the model described by Xu and Zeger (2001) will be negligible.
We used the model proposed by Asparouhov et al. (2006) in this paper. When applying
this model to the EMPHACIS trial data, we let tk ¼ 0:7k;k ¼ 1;2;...;7; because each
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123cycle was 0.7 month. We considered ﬁve trajectory models with (5–6) for the survival
component and the models l_i, l_s, l_is, q_s, and q_sq for the longitudinal component.
These models are named by adding the preﬁx ‘‘traj’’ to the corresponding longitudinal
model name. The path diagram in Fig. 1a represents the trajectory model trajq_s. In the
ﬁgure, the rectangles represent the observed variables, the ellipses represent latent vari-
ables (I for intercept, S for slope, Q for quadratic coefﬁcient, and Y 
k = g(tk)), and the
arrows point to the dependent variables.
(a)
(b)
Fig. 1 Path diagrams of joint models trajq_s and remq_s. Trt treatment; I intercept (b0i); S slope (b1i); Q
quadratic coefﬁcient (b2i); y 
k = g(tk)
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1233.3.2 Shared random-effects model
In the shared random-effects model, the longitudinal component and survival component
are linked through the random-effects bi:
loghiðtÞ¼logh0ðtÞþX0
sia þ b
0
ic: ð8Þ
Similar to the trajectory models, we considered ﬁve choices for the longitudinal component
(l_i, l_s, l_is, q_s, and q_sq), along with (8) for the survival component. These models are
named by adding the preﬁx ‘‘rem’’ to the corresponding longitudinal model name. The path
diagram in Fig. 1b represents the random-effects model remq_s:
giðtÞ¼b0i þ b1it þ b2it2; b0i ¼ b00 þ f0i; b1i ¼ b10 þ b11Zi þ f1i; b2i ¼ b20 þ f2i;
loghiðtÞ¼logh0ðtÞþaZi þ c0b0i þ c1b1i þ c2b2i;
and h0(t) is a non-parametric baseline hazard function. In this setting, it is easy to see a
direct treatment effect (a) on TTPD and an indirect treatment effect (c1b11) on TTPD
through random slopes (b1i). Combining the direct and indirect treatment effects, we
derived the overall treatment effect on TTPD as a ? c1b11. The decomposition of the
overall effect into the direct and indirect effects can be generalized to a non-treatment
covariate if it is incorporated into both the longitudinal and survival components of the
joint model. This feature represents an important advantage of the shared random-effects
model.
We used the software Mplus Version 6 (Muthe ´n and Muthe ´n 1998–2010) to ﬁt the
trajectory models and shared random-effect models using maximum likelihood estimation.
Different joint models were compared using the Bayesian Information Criterion (BIC)
(Schwarz 1978) deﬁned as
BIC ¼  2logLða;c;r;b;RÞþplogðnÞ;
where p is the number of parameters in the model, n is the sample size, and the joint log-
likelihood is given by:
logLða;c;r;b;RÞ¼
X n
i¼1
log
Z
pðTi;dijbi;a;cÞ
Y Ji
j¼1
pðYijjbi;rÞpðbijb;RÞdbi;
pðYijjbi;rÞ¼
1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2pr2 p exp  
ðYij   fðtijÞ
TbiÞ
2
2pr2
()
;
pðbijb;RÞ¼
1
ð2pÞ
r=2jRj
1=2 exp  
1
2
ðbi   bXiÞ
TR 1ðbi   bXiÞ
  
:
In the trajectory model, pðTi;dijbi;a;cÞ is given in (7), and in the shared random-effect
model,
pðTi;dijbi;a;cÞ¼hiðTiÞ
ð1 diÞexp  
Z Ti
0
hiðsÞds
  
with hið Þ given by (8).
The BIC is readily available in Mplus for both trajectory and random-effects models.
The model with a lower value of BIC is preferred. There are many other approaches for
model selection. For example, researchers using Bayesian approaches for joint modeling
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123often use the Deviance Information Criterion (DIC) (Spiegelhalter et al. 2002). Guo and
Carlin (2004) and Hatﬁeld et al. (2011) used the DIC for model selection in joint modeling
and provided rich discussions on the DIC.
4 Results
4.1 Separate analyses
In the MMRM analyses, we used both compound symmetry and AR(1) covariance
matrices. Because the MMRM analyses with AR(1) gave smaller BIC, we reported the
results using the AR(1) covariance matrix in Table 1. The least square mean (LSMean) and
standard error (SE) of the LSMean for each LCSS item in each treatment arm at cycle 6 are
reported, as well as the P-value for testing the difference in LCSS mean score between the
two treatment arms at cycle 6. Signiﬁcantly (or trending to signiﬁcantly) lower mean scores
in pemetrexed/cisplatin were observed on dyspnea, ASBI5, and ASBI8 (P-values\0.1).
For survival data, we ﬁtted the Cox proportional hazards model with treatment as the
only covariate and the hazard ratio (HR) for treatment (pemetrexed/cisplatin versus cis-
platin) was HR0 = 0.73 (P-value = 0.001).
4.2 Cox model with time-varying covariates
The naive method was applied, i.e., each LCSS item was incorporated in the Cox model as
a time-varying covariate. The HRs for a one-point increase in LCSS items and the HRs for
treatment are presented in Table 3 under ‘‘Naive Model’’. The P-values for these HRs were
all less than 0.01, indicating signiﬁcant effects of both LCSS and treatment on TTPD. The
hazard increased approximately from 9 % (cough) to 23 % (ASBI5), with a 10-point
increase in the observed LCSS score.
Table 1 Least square means (LSMean) at cycle 6 from the mixed-effects model for repeated measures
(MMRM) analysis
LCSS item Cisplatin Pemetrexed/cisplatin Difference
LSMean SE LSMean SE P-value
Anorexia 32.4 2.2 32.3 1.9 0.961
Cough 11.8 1.5 10.5 1.3 0.523
Dyspnea 36.9 2.0 30.9 1.7 0.023
Fatigue 44.7 2.1 41.3 1.8 0.218
Pain 28.7 2.0 25.0 1.7 0.157
Interference 48.5 2.0 44.5 1.8 0.136
QoL 47.3 2.0 43.6 1.7 0.164
Symptoms 38.9 2.0 35.4 1.7 0.194
ASBI5 31.6 1.4 28.3 1.2 0.076
ASBI8 36.9 1.4 33.2 1.3 0.053
LCSS Lung Cancer Symptom Scale, ASBI5 the mean of the ﬁve symptom items (anorexia, cough, dyspnea,
fatigue, and pain), ASBI8 the mean of the ﬁve symptom items and the three global items (interference, QoL,
and symptoms). SE standard error
190 Health Serv Outcomes Res Method (2012) 12:182–199
1234.3 Joint models without covariates other than treatment
We jointly modeled TTPD with each LCSS item using the ﬁve trajectory models and the
ﬁve random-effects models described in Sect. 3. Treatment was the only covariate we
considered in both longitudinal and survival components. There were no signiﬁcant
treatment effects on random intercepts in the trajl_i, trajl_is, reml_i, and reml_is models
(all P-values >0:05 except for anorexia in the reml_is with P-value = 0.039). Under the
trajectory model framework, the trajq_s models gave the smallest BIC. Table 2 lists BIC
for the trajq_s models, and BIC differences between the other four trajectory models and
the trajq_s model. Under the random-effects model framework, again using the model q_s
for the longitudinal component led to the smallest BIC. Table 2 lists BIC for the remq_s
model, and BIC differences between the other four random-effects models and the
remq_s model. According to Raftery (1995), under either the trajectory or the random-
effects model framework, the BIC difference between q_s and q_sq represents positive
evidence favoring q_s, and the BIC difference between q_s and the three l models rep-
resents very strong evidence favoring q_s (difference of 0–2, 2–6, 6–10, and[10 repre-
sents weak, positive, strong, and very strong evidence, respectively, of favoring the model
with smaller BIC). Therefore, we chose to present the detailed results from the best models
under each framework, trajq_s and remq_s, in Tables 3 and 4, respectively.
Table 3 shows a signiﬁcant treatment effect on slope of dyspnea (P-value = 0.039)
only, trending to a signiﬁcant treatment effect on slope of ASBI5 (P-value = 0.072) and
ASBI8 (P-value = 0.079). When comparing the HRs of treatment from the trajq_s model
(column e
a) with those from the naive method, the differences were minor. When com-
paring the HRs of the LCSS items, those from trajq_s (column e
c) were all bigger than
those from the naive method. Both phenomena are consistent with the ﬁndings in Ibrahim
et al. (2010). Through simulation, they showed that the naive model and the joint model
give nearly unbiased estimates for the direct treatment effect on survival (i.e., a here) and
the naive model gives the biased estimate towards the null for the association between the
longitudinal process and survival (i.e., c here).
Table 4 provides the parameter estimates for the other joint model, remq_s. There was a
signiﬁcant treatment effect on slope of dyspnea, pain, ASBI5, and ASBI8 (P-values for b11
were less than 0.05). On the one hand, this ﬁnding indicates that there was a signiﬁcant
treatment-by-time interaction effect on the growth of dyspnea, pain, ASBI5, and ASBI8.
On the other hand, because the difference in the mean LCSS scores between the
pemetrexed/cisplatin and cisplatin arms at time point t was b11t under model remq_s, we
could infer that patients in the pemetrexed/cisplatin arm had a signiﬁcantly lower score on
dyspnea, pain, ASBI5, and ASBI8 at cycle 6. This is similar with the ﬁndings in the
MMRM analysis, in which signiﬁcant or trending to signiﬁcant treatment effects at cycle
6 were found on dyspnea, ASBI5, and ASBI8. From the parameter estimates of
(b00, b10, b11, b20), we plotted the ﬁtted mean quadratic growth curves under each treat-
ment arm in Fig. 2 for the four items with a signiﬁcant treatment effect on slope. The
growth curves for pemetrexed/cisplatin are beneath those for cisplatin for all ten items; this
ﬁnding was expected because the estimates for b11 were all negative. These curves show a
beneﬁcial effect of pemetrexed/cisplatin on the progress of the LCSS items.
In Table 4, c0, c1, and c2 measure the association between the random features b0i, b1i,
and b2i of the LCSS trajectory and TTPD. For cough, dyspnea, pain, ASBI5, and ASBI8,
all three features were signiﬁcantly associated with TTPD (P-values for c0, c1 and c2 were
less than 0.01). For symptoms, two features were signiﬁcantly associated with TTPD
(P-value\0.01 for c0 and P-value\0.05 for c1). For the other four items, only the intercept
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123Table 3 Results from the naive method and joint model trajq_s
LCSS Item Naive model Joint Model Trajq_s
HR (LCSS) HR (Trt) b00 b10 b11 b20 e
c: HR (LCSS) e
a: HR (Trt)
Anorexia 1.011 0.67 28.8 5.93 -0.138 -1.15 1.014 0.66
Cough 1.009 0.72 14.7 -1.29 -0.410 0.193 1.015 0.72
Dyspnea 1.010 0.73 32.6 2.74 -1.280* -0.327 1.011 0.73
Fatigue 1.012 0.70 36.4 6.62 -1.033 -1.032 1.014 0.70
Pain 1.016 0.70 26.8 0.63 -0.891 0.061 1.018 0.71
Interference 1.013 0.66 41.5 5.87 -0.881 -0.905 1.015 0.66
QoL 1.012 0.69 41.1 4.86 -0.873 -0.710 1.014 0.69
Symptoms 1.012 0.68 34.1 3.08 -0.805 -0.432 1.014 0.68
ASBI5 1.021 0.69 27.9 3.09 -0.866 -0.435 1.025 0.68
ASBI8 1.019 0.67 32.0 3.72 -0.883 -0.516 1.022 0.67
LCSS Lung Cancer Symptom Scale, ASBI5 the mean of the ﬁve symptom items (anorexia, cough, dyspnea,
fatigue, and pain), ASBI8 the mean of the ﬁve symptom items and the three global items (interference, QoL,
and symptoms), HR hazard ratio, Trt treatment
b00: mean of intercepts b0i in LCSS trajectory gi(t) = b0i ? b1it ? b2it
2
b10: mean of slopes b1i for patients treated with cisplatin
b11: treatment effect on b1i;* P-value\0.05
b10 ? b11: mean of slopes b1i for patients treated with pemetrexed/cisplatin
b20: mean of quadratic coefﬁcient b2i
c: the association between LCSS trajectory and time to progressive disease (TTPD)
P-values for c and a were less than 0.01
Table 4 Results from the remq_s model
LCSS item b00 b10 b11 b20 c0 c1 c2 e
a eaþc1b11
Anorexia 28.8 6.09 -0.37 -1.12 0.018** 0.060 0.293 0.66 0.65
Cough 14.7 -1.24 -0.62 0.26 0.017** 0.083** 0.359** 0.74 0.70
Dyspnea 32.6 2.89 -1.60* -0.25 0.010** 0.064** 0.260** 0.76 0.68
Fatigue 36.3 6.92 -1.29 -1.03 0.014** 0.041 0.104 0.69 0.65
Pain 26.8 0.84 -1.30* 0.16 0.017** 0.087** 0.333** 0.74 0.66
Interference 41.5 6.08 -1.12 -0.88 0.017** 0.040 0.127 0.65 0.62
QoL 41.1 5.05 -1.06 -0.70 0.015** 0.032 0.070 0.67 0.65
Symptoms 34.1 3.26 -1.08 -0.39 0.015** 0.059* 0.219 0.69 0.65
ASBI5 27.9 3.23 -1.17* -0.35 0.024** 0.105** 0.414** 0.71 0.63
ASBI8 32.0 3.86 -1.14* -0.45 0.022** 0.086** 0.317** 0.69 0.62
LCSS Lung Cancer Symptom Scale, ASBI5 the mean of the ﬁve symptom items (anorexia, cough, dyspnea,
fatigue, and pain), ASBI8 the mean of the ﬁve symptom items and the three global items (interference, QoL,
and symptoms). b’s have the same meanings as those in Table 3. c0, c1, c2 measure the association between
random features of the LCSS trajectory and time to progressive disease (TTPD)
In columns b11, c0, c1, and c2,*P-value\0.05, **P-value\0.01
e
a is the direct treatment effect (pemetrexed/cisplatin versus cisplatin) in hazard ratio and eaþc1b11 is the
overall treatment effect in hazard ratio. P-values\0.01 for the direct treatment effects and P-values\0.001
for the overall treatment effects
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123of the trajectory was signiﬁcantly associated with TTPD (P-value\0.01 for c0). Joint tests
on null hypothesis H0: c0 = c1 = c2 = 0 were performed using Wald-tests; the P-values
were all less than 0.001.
TheoveralltreatmenteffectsintermsofHRsarelistedincolumneaþc1b11 inTable 4.They
are consistently smaller than HR0 = 0.73 (i.e., the treatment effect without incorporating
any longitudinal LCSS item), even when the treatment effect on LCSS was not signiﬁcant.
This ﬁnding is consistent with those by Ibrahim et al. (2010) and Chen et al. (2011).
4.4 Joint model with other covariates
In the analyses presented in Sect. 4.3, we did not incorporate any covariates other than
treatment. In this section, we considered six covariates in the model remq_s: bf for B12 and
folic acid supplementation before treatment (bf = 1 if fully supplemented; bf = 0 if never
or partially supplemented), kpsb for baseline Karnofsky performance status (KPS)
(kpsb = 1 if baseline KPS = 90 or 100; kpsb = 0 if baseline KPS = 70 or 80), stagele3
for tumor stage (stagele3 = 1 if tumor stage is III or less; stagele3 = 0 if tumor stage is
IV), agelt65 for age group (agelt65 = 1 if age\65 years old; agelt65 = 0 if age >65 years
old), gender (1 if male, 0 if female) and race (1 if Caucasian, 0 if other). We did not include
treatment and bf in the random intercept sub-model because the intercept represents the
baseline status and is not impacted by post-baseline interventions, such as administration of
treatments or supplementation of B12 and folic acid.
The parameter estimates and their 95 % conﬁdence intervals from the joint model of
ASBI5 are summarized in Fig. 3. From the left plot for the sub-model of the random
Fig. 2 Fitted population-level quadratic growth curve of LCSS scores in the remq_s model. The cisplatin
group is in gray, and the pemetrexed/cisplatin group is in black
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123intercept (b0i), we see a signiﬁcantly smaller intercept of ASBI5 (i.e. less symptoms at
baseline) in men than women, in patients who have better performance status than those
have worse performance status, and in patients who have tumor stage III or less at baseline
than those have tumor stage IV. The middle plot for the sub-model of random slope (b1i)
shows that patients receiving pemetrexed/cisplatin had signiﬁcantly smaller slopes (i.e.,
slower worsening or quicker improving). The right plot for the sub-model of TTPD shows
that all three random effects have signiﬁcantly positive associations with the hazard and
pemetrexed/cisplatin and stage III or less were signiﬁcantly associated with improved
TTPD.
By looking at the same plots for other items, several common ﬁndings are found: (1)
patients with better performance status at baseline had signiﬁcantly smaller intercepts of
the item; (2) At least one random effect showed a signiﬁcant positive association with the
hazard; and (3) Pemetrexed/cisplatin and stage III or less were signiﬁcantly associated with
improved TTPD.
Similar to deriving the overall treatment effect on TTPD, we were able to derive the
overall effect of other covariates from the joint model. Table 5 lists the direct and overall
effects of treatment, kpsb, and stagele3 on TTPD. For every item, the overall kpsb effect
was much larger (i.e., had a lower HR) than its direct effect. This was expected because
kpsb had a signiﬁcant effect on the intercept and the intercept was signiﬁcantly associated
with TTPD for every item. Thus, the indirect effect of kpsb on TTPD through intercept was
big. In contrast, the direct and overall stagele3 effects were similar. The overall treatment
effects were very similar to those from the remq_s model without covariates (see Table 4).
Given this is a randomized study, this was not surprising. However, in a non-randomized
observational study, joint models with covariates may be necessary to reduce bias.
5 Discussion
In this paper, we applied the joint modeling approach to an analysis of longitudinal PRO
and survival outcomes from a clinical trial in patients with mesothelioma. Joint models
Fig. 3 Parameter estimates and 95 % conﬁdence intervals for effects of covariates on random intercepts,
random slopes, and TTPD in the remq_s model for ASBI5 with covariates. Conﬁdence intervals that exclude
the null value of 0 are in black
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123allow us to simultaneously assess treatment effect on both longitudinal PRO and survival
outcomes, as well as the association between these two outcomes. Our joint models pro-
duced different and seemingly more accurate results compared with models focused on
PROs alone, or survival alone, or the naive model ignoring measurement errors in PROs by
directly handling informative censoring and accounting for measurement errors. In addi-
tion, our joint models allowed speciﬁc modeling of PROs with latent trajectory and linked
PROs and TTPD either through a latent trajectory or shared random effects. We compared
our joint modeling approach with several standard approaches that analyzed longitudinal
and survival data separately. Our joint models not only suggested a beneﬁcial treatment
effect on nearly all PRO measures at the end of the treatment period, but also were able to
describe patterns (or trajectories) in PROs throughout the treatment period. Given the large
treatment effect observed on TTPD in this study, both separate and joint modeling
approaches showed a signiﬁcant treatment effect on TTPD. However, the treatment effect
on TTPD appeared to be larger in the joint models, which represented ﬁndings consistent
with Ibrahim et al. (2010) and Chen et al. (2011). These authors showed that when the
longitudinal data are associated with treatment, ignoring the longitudinal data in the sur-
vival model will lead to a biased estimate of the overall treatment effect on survival. In
addition, our joint models allowed us to quantify the direct treatment effect on TTPD, as
well as the indirect treatment effect through PROs.
A few speciﬁc features of the joint models deserve further discussions. First, in our
longitudinal model for PROs, we explored both linear and non-linear trajectories (quadratic
curves). Indeed, data from the mesothelioma trial suggested that the non-linear trajectory
might be a better choice. For all the PRO measures with the exception of cough and pain,
the ﬁtted trajectories showed that PROs appeared to be worse during the ﬁrst 3 months or
the ﬁrst four cycles for both treatment groups, and remained the same or improved after
that. The initial worsening of PROs could be related to a large proportion of patients
experiencing tumor progressions early on during the treatment, and/or the toxicity asso-
ciated with the treatment. The rebound of PROs after 3 months suggested that those
Table 5 Direct and overall effects of treatment, kpsb, and stagele3 on TTPD in terms of hazard ratios
LCSS item Treatment kpsb stagele3
Direct Overall Direct Overall Direct Overall
Anorexia 0.65 0.64 0.88 0.69 0.77 0.72
Cough 0.72 0.68 0.78 0.71 0.72 0.73
Dyspnea 0.74 0.67 0.84 0.69 0.71 0.72
Fatigue 0.68 0.64 0.85 0.67 0.73 0.72
Pain 0.72 0.65 0.81 0.65 0.75 0.70
Interference 0.65 0.62 0.95 0.66 0.75 0.72
QoL 0.67 0.65 0.88 0.66 0.73 0.73
Symptoms 0.68 0.64 0.87 0.65 0.77 0.74
ASBI5 0.71 0.62 0.92 0.64 0.73 0.71
ASBI8 0.69 0.62 0.94 0.63 0.74 0.71
Kpsb baseline Karnofsky performance status (KPS) (kpsb = 1 if baseline KPS = 90 or 100; kpsb = 0i f
baseline KPS = 70 or 80); stagele3 tumor stage (stagele3 = 1 if tumor stage is III or less; stagele3 0 if
tumor stage is IV), TTPD time to progressive disease, LCSS Lung Cancer Symptom Scale, ASBI5 the mean
of the ﬁve symptom items (anorexia, cough, dyspnea, fatigue, and pain), ASBI8 the mean of the ﬁve
symptom items and the three global items (interference, QoL, and symptoms)
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123patients who were alive without tumor progression might have beneﬁted from the treat-
ment either in tumor response or improved tolerability. Further explorations are necessary
to clarify this. Second, we used different functions to link the longitudinal and survival
data: the trajectory function itself or shared random effects (such as slope in the trajectory
function). In our analysis, use of either link function provided similar results (Tables 3, 4)
as long as the shape of the growth curves was speciﬁed as quadratic. Guo and Carlin (2004)
compared several link functions in their joint models, and showed that linking intercept
(initial CD4 level) and the rate of CD4 decrease (slope) to survival provided a better ﬁt in
their analysis of data from AIDS clinical trials. However, their analyses were limited to a
linear growth curve for longitudinal data. In the presence of a non-linear growth curve, use
of the trajectory function as the link might provide a simple interpretation that survival is
inﬂuenced by the current value of the longitudinal outcomes. Third, we showed that
important baseline covariates could be included in our joint model. Our analysis conﬁrmed
the well-known association between performance status and PROs as well as the associ-
ation between the stage of tumor and TTPD. Both performance status and the stage of
tumor are important prognostic factors for TTPD and overall survival. In the setting of our
clinical trials, both performance status and the stage of tumor were included as stratiﬁ-
cation variables in the randomization scheme, so treatment effects remained the same in
the joint model including covariates. However, in a non-randomized observational study,
joint models with covariates may be necessary to reduce bias.
While we have carefully considered our models and analyses, our work has several
limitations. We have modeled each PRO item with TTPD one at a time. While this helped
to establish the association between each PRO item and TTPD, often a treatment impacts
multiple dimensions of PRO simultaneously, and changes in various PRO dimensions are
related. An alternative is to develop a multivariate longitudinal model for all PRO items
and link it to the survival model or reduce PROs to a single score, similar to the use of
ASBI in our analysis. In either part of our joint models, assumptions may be violated either
due to skewness of the PRO data with an excessive amount of zero data (i.e., absence of
symptoms) or non-proportional hazards. Several modiﬁcations may lead to improvement in
the performance of the joint models. For the longitudinal model, one may transform the
PRO scores by a square-root transformation (Ibrahim et al. 2010), use a zero-inﬂated beta
model (Hatﬁeld et al. 2011), or model the change in PROs from baseline, which is more
likely to be normally distributed. For the survival model, we may use alternatives to
proportional hazards models, such as piece-wise exponential or parametric models.
Currently, no standard software exists to ﬁt a wide range of joint models. Indeed, this
presents a computational challenge, impeding the broader use of joint models in practice.
Several authors have developed models that can be implemented in SASr or WinBUGS
(Guo and Carlin 2004; Ibrahim et al. 2010). An R package JM was recently developed for
joint modeling of longitudinal and time-to-event data (Rizopoulos 2010). We chose Mplus
to implement our models. Besides the trajectory and the shared random-effects models,
other possibilities for joint modeling to meet different inference needs can also been
implemented in Mplus, such as predicting survival from growth mixture (Muthe ´n et al.
2009). While Mplus offered great ﬂexibility in modeling longitudinal data with latent
variables (such as the latent growth model, the latent class model, and the growth mixture
model), several modiﬁcations are necessary in order to incorporate these longitudinal
models into the survival model (e.g., creating survival variables on subintervals in joint
models when using the trajectory function as the link). In general, we found most of our
models and their extensions could be easily ﬁt by Mplus using a frequentist-based com-
putational algorithm. The Bayesian package for Mplus is currently under development.
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123As joint models become more commonly used for analyzing multiple clinical outcomes,
there are abundant research opportunities for future work. One that potentially has a
signiﬁcant impact on clinical research and regulatory importance is the examination of the
association between intermediate outcomes (such as TTPD and PROs) and ultimate out-
comes (such as overall survival). A three-way joint model linking TTPD, PRO changes,
and overall survival could be developed (Asparouhov et al. 2006). As various options for
joint models exist, efﬁcient and robust model selection criteria need to be developed in
order to build the best joint models in both Bayesian and frequentist settings. Finally, our
joint models offer a ﬂexible framework in modeling multiple outcomes from clinical
research. The idea of borrowing information across outcome types (such as efﬁcacy and
safety) through carefully selected ﬁxed or random effects is easily generalizable.
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